Continue reading “Vraylar Now Approved for Full Spectrum of Bipolar I Disorder Symptoms”
Bullying Found to Raise Risk for Adolescent Suicide Attempts Worldwide
Trigeminal Nerve Stimulation May Be Effective for Children With ADHD
First Medication Specifically for Postpartum Depression
On 5th March, 2019, FDA approves Spravato(esketamine) nasal spray, a fast-acting novel antidepressant to be used in conjunction with oral antidepressants for treatment refractory depression in adults.
For related information see the American Journal of of psychiatry https://ajp.psychiatryonline.org/…/1…/appi.ajp.2018.17060720